Targeting splicing abnormalities in cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Aberrant splicing is increasingly recognized as a significant factor in cancer development and progression.
• The mechanisms linking aberrant splicing to cancer initiation and advancement are not fully elucidated.
• Splicing alterations can arise from genetic mutations affecting splicing factors or regulatory sequences.

Purpose of the Study:

• To review the landscape of splicing factor mutations observed in various cancers.
• To discuss the downstream splicing consequences resulting from these mutations.
• To highlight current therapeutic strategies targeting the spliceosome in oncology.

Main Methods:

• Literature review of studies on splicing factor mutations in cancer.
• Analysis of reported splicing alterations and their functional impact.
• Survey of ongoing clinical investigations into spliceosome-targeting drugs.

Main Results:

• Splicing factors are frequently mutated across diverse cancer types.
• These mutations lead to widespread changes in messenger RNA splicing patterns.
• Several therapeutic agents targeting the spliceosome are under active investigation for cancer treatment.

Conclusions:

• Mutations in splicing factors represent a critical aspect of cancer biology.
• Understanding these mutations and their consequences is vital for developing novel cancer therapies.
• Targeting the spliceosome offers a promising avenue for future oncological treatments.